Sanders Morris Harris LLC Invests $40,000 in MacroGenics, Inc. (NASDAQ:MGNX)

Sanders Morris Harris LLC acquired a new stake in MacroGenics, Inc. (NASDAQ:MGNX) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,345 shares of the biopharmaceutical company’s stock, valued at approximately $40,000.

A number of other large investors have also added to or reduced their stakes in MGNX. Armistice Capital LLC increased its position in MacroGenics by 150.0% in the 2nd quarter. Armistice Capital LLC now owns 6,000,000 shares of the biopharmaceutical company’s stock valued at $25,500,000 after acquiring an additional 3,600,000 shares during the period. Millennium Management LLC grew its stake in shares of MacroGenics by 3,473.7% in the second quarter. Millennium Management LLC now owns 3,312,672 shares of the biopharmaceutical company’s stock worth $14,079,000 after purchasing an additional 3,219,977 shares during the last quarter. Marshall Wace LLP grew its stake in shares of MacroGenics by 1,689.3% in the second quarter. Marshall Wace LLP now owns 658,007 shares of the biopharmaceutical company’s stock worth $2,797,000 after purchasing an additional 621,232 shares during the last quarter. Frazier Life Sciences Management L.P. increased its holdings in MacroGenics by 21.8% in the second quarter. Frazier Life Sciences Management L.P. now owns 3,010,727 shares of the biopharmaceutical company’s stock valued at $12,796,000 after purchasing an additional 539,023 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in MacroGenics by 39.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 661,914 shares of the biopharmaceutical company’s stock worth $2,178,000 after purchasing an additional 186,858 shares during the last quarter. Institutional investors own 96.89% of the company’s stock.

MacroGenics Stock Performance

MacroGenics stock traded down $0.09 during mid-day trading on Thursday, reaching $3.10. The stock had a trading volume of 28,307 shares, compared to its average volume of 453,615. The firm has a market capitalization of $194.56 million, a PE ratio of -1.96 and a beta of 2.04. MacroGenics, Inc. has a fifty-two week low of $2.95 and a fifty-two week high of $21.88. The stock’s 50-day simple moving average is $3.44 and its 200-day simple moving average is $3.71.

Analyst Ratings Changes

MGNX has been the topic of a number of analyst reports. HC Wainwright reiterated a “neutral” rating and issued a $4.00 price target on shares of MacroGenics in a research report on Wednesday, November 6th. JMP Securities cut MacroGenics from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. Finally, StockNews.com raised shares of MacroGenics from a “sell” rating to a “buy” rating in a research report on Sunday, November 10th. Eight investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.63.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.